Sino Biopharmaceutical (Sino Biopharmaceutical) 3-Year Book Growth Rate : 19.00% (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Sino Biopharmaceutical 3-Year Book Growth Rate?

Sino Biopharmaceutical's Book Value per Share for the quarter that ended in Dec. 2023 was $0.23.

During the past 12 months, Sino Biopharmaceutical's average Book Value per Share Growth Rate was 0.40% per year. During the past 3 years, the average Book Value per Share Growth Rate was 19.00% per year. During the past 5 years, the average Book Value per Share Growth Rate was 21.50% per year. During the past 10 years, the average Book Value per Share Growth Rate was 20.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Sino Biopharmaceutical was 75.30% per year. The lowest was -30.70% per year. And the median was 18.35% per year.

Competitive Comparison of Sino Biopharmaceutical's 3-Year Book Growth Rate

For the Biotechnology subindustry, Sino Biopharmaceutical's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sino Biopharmaceutical's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's 3-Year Book Growth Rate falls into.

Sino Biopharmaceutical 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Sino Biopharmaceutical (OTCPK:SBMFF) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Sino Biopharmaceutical 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical (Sino Biopharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBMFF) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

SBHMY:USA 01177:Hong Kong SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.